Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
October 25, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24...
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
October 12, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
October 05, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
September 08, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 10, 2021 07:05 ET
|
Finch Therapeutics Group, Inc.
Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development programTopline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in...
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
August 10, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
Finch to transfer FIN-524 program to Takeda for clinical developmentFinch and Takeda to continue discovery efforts targeting Crohn’s disease SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE)...
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
June 28, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
May 28, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 13, 2021 07:00 ET
|
Finch Therapeutics Group, Inc.
Completed upsized IPO, raising $130.8 million in gross proceedsTopline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2...